Table 3.
NYHA functional class and biomarkers (Kruskal–Wallis analysis, average rank, and mean ± SD for all parameters) for patients with CIHF
| NYHA class (n) | BNP | IMA | IMAR | Adj-IMA | TAS | TOS | OSI | Albumin |
|---|---|---|---|---|---|---|---|---|
| II (12) | 13.4 | 24.2 | 21.5 | 26.7 | 22.1 | 34 | 35.7 | 34.2 |
| 291 ± 235 | 0.60 ± 0.2 | 0.18 ± 0.05 | 0.46 ± 0.1 | 2.4 ± 0.5 | 7.8 ± 4.9 | 0.3 ± 0.2 | 3.3 ± 0.4 | |
| III (28) | 26.7 | 30.6 | 30.2 | 31.4 | 27.7 | 26.8 | 26.5 | 29.5 |
| 567 ± 347 | 0.51 ± 0.1 | 0.21 ± 0.09 | 0.50 ± 0.1 | 2.6 ± 0.3 | 5.5 ± 4.5 | 0.21 ± 0.1 | 3.1 ± 0.3 | |
| IV(15) | 42.1 | 26 | 29.1 | 22.6 | 33.1 | 25.4 | 24.6 | 20.1 |
| 1161 ± 671 | 0.64 ± 0.2 | 0.21 ± 0.10 | 0.42 ± 0.1 | 2.6 ± 0.4 | 5.5 ± 5.6 | 0.20 ± 0.2 | 2.9 ± 0.4 | |
| P | < 0.0001 | 0.43 | 0.27 | 0.21 | 0.20 | 0.32 | 0.15 | 0.04 |
Significant values are shown in bold.
ABSU, absorbance units; adj-IMA, albumin-adjusted IMA; BNP, brain natriuretic peptide; IMA, ischemia-modified albumin; OSI, oxidative stress index; TAS, total antioxidant status; TOS, total oxidant status.